組換えタンパク質の市場規模、シェア、動向分析レポート宿主細胞別（昆虫細胞、哺乳類）、用途別（研究、治療薬）、製品・サービス別、エンドユーザー別、地域別、セグメント別予測、2022年～2030年

組換えタンパク質市場の成長と動向

Grand View Research, Inc.の新しいレポートによると、組み換えタンパク質の世界市場規模は、予測期間中に12.0%のCAGRを記録し、2030年までに50億9000万米ドルに達すると予測されています。多発性硬化症、好中球減少症、脳溢血、貧血などの疾患や小人症が一般的になりつつあり、組換えタンパク質医薬品の需要を押し上げています。さらに、バイオシミラー、生物製剤、組換えタンパク質の開発への注力は、がんの発生率や有病率の上昇、研究開発活動の拡大のために増加しています。

米国がん協会によると、2022年には新たに190万人のがん患者が発生し、609,360人ががんに関連した死亡をすると予測されています。また、ELISA、ウェスタンブロッティング、免疫組織化学（IHC）などの臨床診断法における遺伝子組換えタンパク質の用途拡大が、市場拡大の原動力になると予想されています。研究開発費の増加、がん患者数の増加、新規治療やオーダーメイド治療への要望などの要因により、予測期間中に世界の産業は大幅に拡大すると予想されています。組換えタンパク質分野の研究活動は、ウイルスの力学を理解するための努力の結果、COVID-19パンデミックに対応して増加しています。組換えタンパク質の生産は、オーダーメイドの治療とともに大幅に増加しました。

さらに、研究資金がより容易に入手できるようになり、組換えタンパク質、特にCOVID-19に関連する免疫反応タンパク質の需要と生産が増加すると予測されます。組換えタンパク質は、天然タンパク質の改良版と見なされ、タンパク質の生産量を向上させ、有用な商業製品を作り、遺伝子配列を変更するために多くの方法で生産することができます。製薬会社の研究開発費の増加、慢性疾患の高い発生率、規制要件の増加、ウイルス感染を減らす必要性の継続が、世界の産業の主な推進力となっています。

予測期間中、世界の産業は組換えタンパク質の合成における技術的進歩によって牽引されると予想されます。例えば、2022年6月、米国バイオテクノロジー情報センターが作成したデータによると、CRISPR/Cas9、TALEN、Zinc Finger mediatedなどの新しい育種技術や、トランスジェニックまたはシスジェニック技術は、体外遺伝子編集または遺伝子操作がより簡単に承認される可能性のある新しい技術であり、そのような技術もあります。また、人口の高齢化、所得水準の向上、より良いヘルスケアインフラ、医療費の増加、新興国での低コスト製造の利点から、業界関係者はこの地域に投資すると予想され、市場成長を後押ししています。

組み換えタンパク質市場のレポートハイライト

製品・サービス別では、2021年に製品分野が最大の売上シェアを占めています。生物医学研究における組換えタンパク質製品の必要性と、癌との闘いにおける研究開発への資金提供の増加により、世界的に需要が高まっている

代謝異常、癌、遺伝子疾患、免疫疾患などの様々な疾患の蔓延により、治療薬用途セグメントが2021年に最大の収益シェアを占めました。

製薬・バイオテクノロジー企業のエンドユーザー部門は、研究の生産性を向上させ、収益創出のための製品提供を拡大するために、主要な市場プレーヤーが研究開発部門に投資を増やしていることから、2021年に世界の産業をリードしました。

哺乳類系は組換えタンパク質の生産に広く使用されているため、このセグメントは2021年に最大の収益シェアを占めた

北米は、慢性疾患の発生率の増加、最先端の治療法の使用、主要プレイヤーの存在、医療費の増加により、2021年に支配的な地域となりました。

研究開発活動の活発化、可処分所得の増加、タンパク質治療に対する患者の理解の向上により、予測期間中、アジア太平洋地域が最も速い速度で成長すると予想されます。

さらに、アジア太平洋地域ではインドと中国が急成長を遂げると予想される

目次

第1章 調査手法

• 市場セグメンテーションと範囲
• 調査手法
• 情報調達
  • 購入したデータベース
  • Gvrの内部データベース
  • 二次情報
  • 1次調査
  • 1次調査の詳細
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ1：コモディティフローアプローチ
    • アプローチ2：ボトムアップアプローチを使用した国別の市場推定
• 世界市場：CAGR計算
• 調査の仮定
• 二次情報のリスト
• 一次情報のリスト
• 目的

第2章 エグゼクティブサマリー

• 市場の見通し
• 市場概要

第3章 市場変数、動向、範囲

• 市場動向と展望
• 市場セグメンテーションと範囲
• 市場力学
  • 市場促進要因分析
    • 医薬品開発と精密医療のための調査活動の増加
    • 生物製剤とバイオシミラーの採用の増加
    • 研究開発活動への投資の増加
  • 市場制約分析
    • タンパク質生産に関する規制および安全上の懸念
    • 熟練した人材と専門知識の不足
  • 市場機会分析
    • 治療用組換えタンパク質のコスト低下とバイオシミラーの出現
    • 革新的な技術により、組換えタンパク質の生産コストを削減できます
• ビジネス環境分析ツール
  • 害虫にSWOT分析
  • ポーターのファイブフォース分析
• 製品の浸透と成長の見通しマッピング、2021
• 組換えタンパク質市場： COVID-19の影響分析

第4章 製品セグメント分析

• 組換えタンパク質市場：製品変動分析
• 製品
  • サイトカインと成長因子
    • インターフェロン
    • インターロイキン
    • その他
  • 抗体
  • 免疫チェックポイントタンパク質
  • ウイルス抗原
  • 酵素
    • キナーゼ
    • 代謝酵素
    • その他
  • 組換え調節タンパク質
  • ホルモン
  • その他
• 制作サービス

第5章 アプリケーションセグメント分析

• 組換えタンパク質市場：アプリケーションの変動分析
• 創薬と開発
• 治療学
  • 生物製剤
  • ワクチン
  • 細胞・遺伝子治療
  • その他
• 調査
• 他の

第6章 エンドユーザーセグメントの分析

• 組換えタンパク質市場：エンドユーザーの変動分析
• 製薬およびバイオテクノロジー企業
• 学術・調査機関
• 診断検査室
• その他

第7章 宿主細胞セグメント分析

• 組換えタンパク質市場：宿主細胞の変動分析
• 哺乳類のシステム
• 昆虫細胞
• 酵母と菌類
• 細菌細胞
• その他

第8章 地域の見通し

• 組換えタンパク質市場：地域変動分析
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東およびアフリカ（Mea）
  • 南アフリカ
  • 宇江
  • サウジアラビア

第9章 競合情勢

• 戦略的枠組み
• 市場参加の分類
• 企業プロファイル
  • Thermo Fisher Scientific, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Abcam plc
    • 会社概要
    • 財務実績
    • 製品/サービスのベンチマーク
    • 戦略的イニシアチブ
  • Bio-Rad Laboratories, Inc.
    • 会社概要
    • 財務実績
    • 製品/サービスのベンチマーク
    • 戦略的イニシアチブ
  • Bio-Techne Corporation
    • 会社概要
    • 研究開発体制
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Merck KGaA
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • GenScript Biotech Corporation
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • RayBiotech Life, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Proteintech Group, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Enzo Life Sciences, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • STEMCELL Technologies Inc
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Sino Biological, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Abnova Corporation
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ

List of Tables

• TABLE 1 List of Secondary Sources
• TABLE 2 List of Abbreviations
• TABLE 3 Global Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 4 Global Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 5 Global Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 6 Global Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 7 Global Recombinant Protein Market, by Region, 2018 - 2030 (USD Million)
• TABLE 8 North America Recombinant Protein Market, by Country, 2018 - 2030 (USD Million)
• TABLE 9 North America Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 10 North America Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 11 North America Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 12 North America Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 13 US Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 14 US Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 15 US Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 16 US Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 17 Canada Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 18 Canada Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 19 Canada Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 20 Canada Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 21 Europe Recombinant Protein Market, by Country, 2018 - 2030 (USD Million)
• TABLE 22 Europe Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 23 Europe Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 24 Europe Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 25 Europe Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 26 Germany Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 27 Germany Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 28 Germany Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 29 Germany Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 30 UK Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 31 UK Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 32 UK Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 33 UK Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 34 France Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 35 France Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 36 France Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 37 France Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 38 Italy Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 39 Italy Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 40 Italy Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 41 Italy Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 42 Spain Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 43 Spain Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 44 Spain Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 45 Spain Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 46 Asia Pacific Recombinant Protein Market, by Country, 2018 - 2030 (USD Million)
• TABLE 47 Asia Pacific Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 48 Asia Pacific Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 49 Asia Pacific Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 50 Asia Pacific Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 51 China Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 52 China Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 53 China Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 54 China Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 55 Japan Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 56 Japan Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 57 Japan Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 58 Japan Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 59 India Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 60 India Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 61 India Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 62 India Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 63 South Korea Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 64 South Korea Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 65 South Korea Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 66 South Korea Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 67 Australia Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 68 Australia Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 69 Australia Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 70 Australia Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 71 Latin America Recombinant Protein Market, by Country, 2018 - 2030 (USD Million)
• TABLE 72 Latin America Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 73 Latin America Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 74 Latin America Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 75 Latin America Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 76 Brazil Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 77 Brazil Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 78 Brazil Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 79 Brazil Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 80 Mexico Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 81 Mexico Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 82 Mexico Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 83 Mexico Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 84 Argentina Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 85 Argentina Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 86 Argentina Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 87 Argentina Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 88 Middle East & Africa Recombinant Protein Market, by Country, 2018 - 2030 (USD Million)
• TABLE 89 Middle East & Africa Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 90 Middle East & Africa Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 91 Middle East & Africa Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 92 Middle East & Africa Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 93 South Africa Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 94 South Africa Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 95 South Africa Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 96 South Africa Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 97 Saudi Arabia Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 98 Saudi Arabia Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 99 Saudi Arabia Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 100 Saudi Arabia Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)
• TABLE 101 UAE Recombinant Protein Market, by Product & Services, 2018 - 2030 (USD Million)
• TABLE 102 UAE Recombinant Protein Market, by Application, 2018 - 2030 (USD Million)
• TABLE 103 UAE Recombinant Protein Market, End-use, 2018 - 2030 (USD Million)
• TABLE 104 UAE Recombinant Protein Market, Host Cell, 2018 - 2030 (USD Million)

List of Figures

• FIG. 1 Market research process
• FIG. 2 Information Procurement
• FIG. 3 Primary Research Pattern
• FIG. 4 Market Research Approaches
• FIG. 5 Value Chain-Based Sizing & Forecasting
• FIG. 6 Market Formulation & Validation
• FIG. 7 Recombinant Protein, Market Segmentation
• FIG. 8 Market Snapshot, 2021
• FIG. 9 Market Trends & Outlook
• FIG. 10 Market Driver Relevance Analysis (Current & Future Impact)
• FIG. 11 Market Restraint Relevance Analysis (Current & Future Impact)
• FIG. 12 Market Challenge Relevance Analysis (Current & Future Impact)
• FIG. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• FIG. 14 Porter's Five Forces Analysis
• FIG. 15 Market Penetration Vs Growth Prospect Mapping, 2021
• FIG. 16 Global Recombinant Protein Market: Product & Services Movement Analysis
• FIG. 17 Global Recombinant Protein Market, for Product, 2018 - 2030 (USD Million)
• FIG. 18 Global Recombinant Protein Market, for Production Services, 2018 - 2030 (USD Million)
• FIG. 19 Global Recombinant Protein Market: Application Movement Analysis
• FIG. 20 Global Recombinant Protein Market, for Drug Discovery & Development, 2018 - 2030 (USD Million)
• FIG. 21 Global Recombinant Protein Market, for Therapeutics, 2018 - 2030 (USD Million)
• FIG. 22 Global Recombinant Protein Market, for Research , 2018 - 2030 (USD Million)
• FIG. 23 Global Recombinant Protein Market, for Others, 2018 - 2030 (USD Million)
• FIG. 24 Global Recombinant Protein Market: End Use Movement Analysis
• FIG. 25 Global Recombinant Protein Market, for Pharma & Biotechnology Companies, 2018 - 2030 (USD Million)
• FIG. 26 Global Recombinant Protein Market, for Academic & Research Institutes, 2018 - 2030 (USD Million)
• FIG. 27 Global Recombinant Protein Market, for Diagnostic Laboratories, 2018 - 2030 (USD Million)
• FIG. 28 Global Recombinant Protein Market, for Others , 2018 - 2030 (USD Million)
• FIG. 29 Global Recombinant Protein Market: Host Cell Movement Analysis
• FIG. 30 Global Recombinant Protein Market, for Mammalian systems, 2018 - 2030 (USD Million)
• FIG. 31 Global Recombinant Protein Market, for Insect Cells, 2018 - 2030 (USD Million)
• FIG. 32 Global Recombinant Protein Market, for Yeast & Fungi, 2018 - 2030 (USD Million)
• FIG. 33 Global Recombinant Protein Market, for Bacterial Cells, 2018 - 2030 (USD Million)
• FIG. 34 Global Recombinant Protein Market, for Others , 2018 - 2030 (USD Million)
• FIG. 35 Regional Marketplace: Key Takeaways
• FIG. 36 Regional Outlook, 2021 & 2030
• FIG. 37 Global Recombinant Protein Market: Region Movement Analysis
• FIG. 38 North America Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 39 US Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 40 Canada Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 41 Europe Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 42 Germany Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 43 UK Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 44 France Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 45 Italy Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 46 Spain Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 47 Asia Pacific Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 48 Japan Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 49 China Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 50 India Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 51 Australia Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 52 South Korea Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 53 Latin America Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 54 Brazil Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 55 Mexico Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 56 Argentina Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 57 Middle East and Africa Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 58 South Africa Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 59 Saudi Arabia Recombinant Protein Market, 2018 - 2030 (USD Million)
• FIG. 60 UAE Recombinant Protein Market, 2018 - 2030 (USD Million)

Recombinant Proteins Market Growth & Trends:

The global recombinant proteins market size is expected to reach USD 5.09 billion by 2030, registering a CAGR of 12.0% over the forecast period, according to a new report by Grand View Research, Inc. Diseases like multiple sclerosis, neutropenia, cerebral apoplexy, anemia, and others, as well as dwarfism, are becoming more common, which is driving up the demand for recombinant protein drugs. Furthermore, the industry is anticipated to expand due to the increased development and research on biologics, which, in turn, are significantly boosting global industry growth.The focus on the development of biosimilars, biologics, and recombinant proteins has increased owing to a rise in the incidence and prevalence of cancer and the expansion of research & development activity.

According to the American Cancer Society, in 2022, there will be 1.9 million new cases of cancer and 609,360 cancer-related deaths. In addition, the expanding application of recombinant proteins in clinical diagnostic methods including ELISA, Western Blotting, and Immunohistochemistry (IHC) is anticipated to fuel market expansion. Due to factors including rising R&D spending, an increase in the number of cancer patients, and the desire for novel & tailored therapies, the global industry is anticipated to expand significantly during the forecast period.Research activity in recombinant protein space has increased in response to the COVID-19 pandemic as a result of efforts to comprehend the dynamics of the virus. The production of recombinant proteins has increased significantly, along with tailored treatment.

In addition, research funding is predicted to become more readily available along with an increase in demand for and production of recombinant proteins, particularly those immune response proteins associated with COVID-19. Therefore, positive effects have been seen for the companies offering products specifically made for COVID-19.Recombinant protein is viewed as a modified version of natural protein that can be produced in a number of ways to improve protein output, create useful commercial goods, and alter gene sequences. The rise in pharmaceutical firms' R&D expenditures, high incidence of chronic illnesses, an increase in the number of regulatory requirements, and the ongoing need to reduce viral infections are the main drivers of the global industry.

Over the projected period, the global industry is anticipated to be driven by technological advancements in the synthesis of recombinant proteins. For instance, in June 2022, according to the data produced by the National Center for Biotechnology Information, new breeding techniques, such as CRISPR/Cas9, TALEN, and Zinc Finger mediated, as well as transgenic or cis-genic techniques, are emerging technologies that may make it easier for in vitro genetic editing or manipulation of the genes to be approved. In addition, industry participants are anticipated to invest in the region due to the aging population, rising income levels, better healthcare infrastructure, rising healthcare spending, and the advantages of low-cost manufacturing in developing nations, thereby propelling market growth.

Recombinant Proteins Market Report Highlights:

• By product & services, the product segment accounted for the largest revenue share in 2021. The demand is increasing globally due to the need for recombinant protein products in biomedical research and increased funding for R&D in the fight against cancer

• The therapeutics application segment held themaximum revenue share in 2021 due to the prevalence of various diseases, such as metabolic disorders, cancer, genetic disorders, and immune diseases

• The pharma & biotech companies end-user segment led the global industry in 2021 due to the increasing investments by key market players in their R&D segment to increase research productivity and grow their offerings for revenue generation

• Mammalian systems are widely used in the production of recombinant proteins, thus, this segment accounted for the largest revenue share in 2021

• North America was the dominant region in 2021 dueto an increase in the incidence of chronic diseases, use of cutting-edge treatments, presence of key players, and rise in healthcare spending in the region

• Asia Pacific is expected to grow at the fastestCAGRover the projected period due to an uptick in R&D activity, an increase in disposable incomes, and a better understanding of protein therapies among patients

• India and China are additionally anticipated to see rapid growth in the AsiaPacific region

Table of Contents

Chapter 1 Research Methodology

• 1.1 Market Segmentation & Scope
  • 1.1.1 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.1.2 Approach 2: Country-Wise Market Estimation Using Bottom-Up Approach
• 1.7 Global Market: Cagr Calculation
• 1.8 Research Assumptions
• 1.9 List Of Secondary Sources
• 1.10 List Of Primary Sources
• 1.11 Objectives
  • 1.11.1 Objective 1:
  • 1.11.2 Objective 2:

Chapter 2 Executive Summary

• 2.1 Market Outllook
• 2.2 Market Summary

Chapter 3 Market Variables, Trends & Scope

• 3.1 Market Trends & Outlook
• 3.2 Market Segmentation And Scope
• 3.3 Market Dynamics
  • 3.3.1 Market Driver Analysis
    • 3.3.1.1 Growing Research Activities For Drug Development And Precision Medicine
    • 3.3.1.2 Rising Adoption Of Biologics And Biosimilars
    • 3.3.1.3 Increasing Investments In Research & Development Activities
  • 3.3.2 Market Restraint Analysis
    • 3.3.2.1 Regulatory And Safety Concerns With Protein Production
    • 3.3.2.2 Dearth Of Skilled Personnel And Expertise
  • 3.3.3 Market Opportunity Analysis
    • 3.3.3.1 Declining Cost Of Therapeutics Recombinant Proteins And Advent Of Biosimilars
    • 3.3.3.2 Innovative Techniques Can Decrease The Recombinant Protein Production Cost
• 3.4 Business Environment Analysis Tools
  • 3.4.1 Swot Analysis, By Pest
  • 3.4.2 Porter's Five Forces Analysis
• 3.5 Penetration & Growth Prospect Mapping For Product, 2021
• 3.6 Recombinant Proteins Market: Covid-19 Impact Analysis

Chapter 4 Product Segment Analysis

• 4.1 Recombinant Proteins Market: Product Movement Analysis
• 4.2 Product
  • 4.2.1 Global Recombiant Proteins Product Market, 2018 - 2030 (USD Million)
  • 4.2.2 Cytokines &Growth Factors
    • 4.2.2.1 Global Cytokines & Growth Factors Market, 2018 - 2030 (USD Million)
    • 4.2.2.1.1 Interferons
    • 4.2.2.1.1.1 Global Interferons Market, 2018 - 2030 (USD Million)
    • 4.2.2.1.2 Interleukins
    • 4.2.2.1.2.1 Global Interleukins Market, 2018 - 2030 (USD Million)
    • 4.2.2.1.3 Others
    • 4.2.2.1.3.1 Others Cytokines & Growth Factors Market, 2018 - 2030 (USD Million)
  • 4.2.3 Antibodies
    • 4.2.3.1 Global Antibodies Market, 2018 - 2030 (USD Million)
  • 4.2.4 Immune Checkpoint Proteins
    • 4.2.4.1 Global Immune Checkpoint Proteins Market, 2018 - 2030 (USD Million)
  • 4.2.5 Virus Antigens
    • 4.2.5.1 Global Virus Antigens Market, 2018 - 2030 (USD Million)
  • 4.2.6 Enzymes
    • 4.2.6.1 Global Enzymes Market, 2018 - 2030 (USD Million)
    • 4.2.6.1.1 Kinases
    • 4.2.6.1.1.1 Global Kinases Market, 2018 - 2030 (USD Million)
    • 4.2.6.1.2 Metabolic Enzymes
    • 4.2.6.1.2.1 Global Metabolic Enzymes Market, 2018 - 2030 (USD Million)
    • 4.2.6.1.3 Others
    • 4.2.6.1.3.1 Others Enzymes Market, 2018 - 2030 (USD Million)
  • 4.2.7 Recombinant Regulatory Proteins
    • 4.2.7.1 Global Recombinant Regulatory Proteins Market, 2018 - 2030 (USD Million)
  • 4.2.8 Hormones
    • 4.2.8.1 Global Hormones Market, 2018 - 2030 (USD Million)
  • 4.2.9 Others
    • 4.2.9.1 Others Product Market, 2018 - 2030 (USD Million)
• 4.3 Production Services
  • 4.3.1 Global Recombiant Proteins Production Services Market, 2018 - 2030 (USD Million)

Chapter 5 Application Segment Analysis

• 5.1 Recombinant Proteins Market: Application Movement Analysis
• 5.2 Drug Discovery & Development
  • 5.2.1 Global Drug Discovery & Development, 2018 - 2030 (USD Million)
• 5.3 Therapeutics
  • 5.3.1 Global Therpeutics Market, 2018 - 2030 (USD Million)
  • 5.3.2 Biologics
    • 5.3.2.1 Global Biologics Market, 2018 - 2030 (USD Million)
  • 5.3.3 Vaccines
    • 5.3.3.1 Global Vaccines Market, 2018 - 2030 (USD Million)
  • 5.3.4 Cell & Gene Therapies
    • 5.3.4.1 Global Cell & Gene Therapies Market, 2018 - 2030 (USD Million)
  • 5.3.5 Others
    • 5.3.5.1 Others Therapeutics Market, 2018 - 2030 (USD Million)
• 5.4 Research
  • 5.4.1 Global Research Market, 2018 - 2030 (USD Million)
• 5.5 Other
  • 5.5.1 Other Application Market, 2018 - 2030 (USD Million)

Chapter 6 End-User Segment Analysis

• 6.1 Recombinant Proteins Market: End-User Movement Analysis
• 6.2 Pharmaceutical & Biotechnology Companies
  • 6.2.1 Global Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
• 6.3 Academic & Research Institutes
  • 6.3.1 Global Academic & Research Institutes Market, 2018 - 2030 (USD Million)
• 6.4 Diagnostic Laboratories
  • 6.4.1 Global Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
• 6.5 Others
  • 6.5.1 Other End-Users, 2018 - 2030 (USD Million)

Chapter 7 Host-Cells Segment Analysis

• 7.1 Recombinant Proteins Market: Host-Cells Movement Analysis
• 7.2 Mammalian Systems
  • 7.2.1 Global Mammalian Systems Market, 2018 - 2030 (USD Million)
• 7.3 Insects Cells
  • 7.3.1 Global Insects Cells Market, 2018 - 2030 (USD Million)
• 7.4 Yeast & Fungi
  • 7.4.1 Global Yeast & Fungi Market, 2018 - 2030 (USD Million)
• 7.5 Bacterial Cells
  • 7.5.1 Global Bacterial Cells Market, 2018 - 2030 (USD Million)
• 7.6 Others
  • 7.6.1 Other Host-Cells, 2018 - 2030 (USD Million)

Chapter 8 Regional Outlook

• 8.1 Recombinant Proteins Market: Regional Movement Analysis
• 8.2 North America
  • 8.2.1 North America Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.2.2 U.S.
    • 8.2.2.1 U.S. Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.2.3 Canada
    • 8.2.3.1 Canada Recombinant Proteins Market, 2018 - 2030 (USD Million)
• 8.3 Europe
  • 8.3.1 Europe Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.3.2 U.K.
    • 8.3.2.1 U.K. Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.3.3 Germany
    • 8.3.3.1 Germany Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.3.4 France
    • 8.3.4.1 France Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.3.5 Italy
    • 8.3.5.1 Italy Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.3.6 Spain
    • 8.3.6.1 Sain Recombinant Proteins Market, 2018 - 2030 (USD Million)
• 8.4 Asia Pacific
  • 8.4.1 Asia Pacific Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.4.2 China
    • 8.4.2.1 China Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.4.3 India
    • 8.4.3.1 India Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.4.4 Japan
    • 8.4.4.1 Japan Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.4.5 South Korea
    • 8.4.5.1 South Korea Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.4.5 Australia
    • 8.4.5.1 Australia Recombinant Proteins Market, 2018 - 2030 (USD Million)
• 8.5 Latin America
  • 8.5.1 Latin America Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.5.2 Brazil
    • 8.5.2.1 Brazil Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.5.3 Mexico
    • 8.5.3.1 Mexico Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.5.4 Argentina
    • 8.5.4.1 Argentina Recombinant Proteins Market, 2018 - 2030 (USD Million)
• 8.6 Middle East And Africa (Mea)
  • 8.6.1 Mea Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.6.2 South Africa
    • 8.6.2.1 South Africa Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.6.3 Uae
    • 8.6.3.1 Uae Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 8.6.4 Saudi Arabia
    • 8.6.4.1 Saudi Arabia Recombinant Proteins Market, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape

• 9.1 Strategy Framework
• 9.2 Market Participation Categorization
• 9.3 Company Profiles
  • 9.3.1 Thermo Fisher Scientific, Inc.
    • 9.3.1.1 Company Overview
    • 9.3.1.2 Financial Performance
    • 9.3.1.3 Product Benchmarking
    • 9.3.1.4 Strategic Initiatives
  • 9.3.2 Abcam plc
    • 9.3.2.1 Company Overview
    • 9.3.2.2 Financial Performance
    • 9.3.2.3 Product/Service Benchmarking
    • 9.3.2.4 Strategic Initiatives
  • 9.3.3 Bio-Rad Laboratories, Inc.
    • 9.3.3.1 Company Overview
    • 9.3.3.2 Financial Performance
    • 9.3.3.3 Product/Service Benchmarking
    • 9.3.3.4 Strategic Initiatives
  • 9.3.4 Bio-Techne Corporation
    • 9.3.4.1 Company Overview
    • 9.3.4.1.1 R&D Systems
    • 9.3.4.2 Financial Performance
    • 9.3.4.3 Product Benchmarking
    • 9.3.4.4 Strategic Initiatives
  • 9.3.5 Merck KGaA
    • 9.3.5.1 Company Overview
    • 9.3.5.2 Financial Performance
    • 9.3.5.3 Product Benchmarking
    • 9.3.5.4 Strategic Initiatives
  • 9.3.6 GenScript Biotech Corporation
    • 9.3.6.1 Company Overview
    • 9.3.6.2 Financial Performance
    • 9.3.6.3 Product Benchmarking
    • 9.3.6.4 Strategic Initiatives
  • 9.3.7 RayBiotech Life, Inc.
    • 9.3.7.1 Company Overview
    • 9.3.7.2 Financial Performance
    • 9.3.7.3 Product Benchmarking
    • 9.3.7.4 Strategic Initiatives
  • 9.3.8 Proteintech Group, Inc.
    • 9.3.8.1 Company Overview
    • 9.3.8.2 Financial Performance
    • 9.3.8.3 Product Benchmarking
    • 9.3.8.4 Strategic Initiatives
  • 9.3.9 Enzo Life Sciences, Inc.
    • 9.3.9.1 Company Overview
    • 9.3.9.2 Financial Performance
    • 9.3.9.3 Product Benchmarking
    • 9.3.9.4 Strategic Initiatives
  • 9.3.10 STEMCELL Technologies Inc
    • 9.3.10.1 Company Overview
    • 9.3.10.2 Financial Performance
    • 9.3.10.3 Product Benchmarking
    • 9.3.10.4 Strategic Initiatives
  • 9.3.11 Sino Biological, Inc.
    • 9.3.11.1 Company Overview
    • 9.3.11.2 Financial Performance
    • 9.3.11.3 Product Benchmarking
    • 9.3.11.4 Strategic Initiatives
  • 9.3.12 Abnova Corporation
    • 9.3.12.1 Company Overview
    • 9.3.12.2 Financial Performance
    • 9.3.12.3 Product Benchmarking
    • 9.3.12.4 Strategic Initiatives